Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Apple Turns 50: From Garage Startup to AI Crossroads 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
RESEARCH TRIANGLE PARK, N.C., July 24, 2017 -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today that its second quarter 2017 financial results will be reported on Monday, August 7, 2017.
BioCryst will host a conference call and webcast at 11:00 a.m. Eastern Time to discuss financial results and to provide an update regarding the Company's clinical development programs. The call will be led by Jon P. Stonehouse, President & Chief Executive Officer, Thomas R. Staab II, Senior Vice President & Chief Financial Officer, and Dr. Bill Sheridan, Senior Vice President and Chief Medical Officer.
Links to a live audio webcast and replay of the presentation may be accessed on the BioCryst website events page at http://investor.shareholder.com/biocryst/events.cfm.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals designs, optimizes and develops novel small molecule drugs that block key enzymes involved in rare diseases. BioCryst has several ongoing development programs: BCX7353 and other second generation oral inhibitors of plasma kallikrein for hereditary angioedema, and galidesivir, a broad spectrum viral RNA polymerase inhibitor that is a potential treatment for filoviruses. RAPIVAB® (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, is BioCryst's first approved product and has received regulatory approval in the U.S., Canada, Japan, Taiwan and Korea. Post-marketing commitment development activities for RAPIVAB are ongoing, as well as activities to support regulatory approvals in other territories. For more information, please visit the Company's website at www.BioCryst.com.
This press release contains forward-looking statements, including statements regarding future results and achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Please refer to the documents BioCryst files periodically with the SEC and located at http://investor.shareholder.com/biocryst/sec.cfm.
BCRXW
CONTACT: Thomas Staab, BioCryst Pharmaceuticals, +1-919-859-7910
